Sold as Axert. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Almotriptan Malate (sold as Axert), first approved May 7, 2001, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Almotriptan Malate | Part D | $1.5M | 0% | 1,375 |
| May 7, 2001 | AxertNDA 21001 · New molecular entity | Janssen Pharms | 8 | Discontinued |
| Jul 7, 2015 | Almotriptan MalateANDA 78027 | Teva Pharms USA | 1 | Marketed |
| Nov 9, 2015 | Almotriptan MalateANDA 205171 | Mylan | 1 | Marketed |
| Mar 3, 2016 | Almotriptan MalateANDA 205523 | Ajanta Pharma Ltd | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Mylan